Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).

Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.

Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.

Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.

Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.

A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.

Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.

A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.

Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.

Before shifting focus away from non-metastatic castration-resistant prostate cancer, medical oncologists reflect on means to optimize care and look to future directions in the field.

Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.

A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.

Key opinion leaders reflect on the real-world use and data behind AR inhibitors in non-metastatic castration-resistant prostate cancer.

Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.

Expert oncologists provide a focused review on goals of therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Expert oncologists Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, reflect on the current treatment paradigm for patients with metastatic castration-resistant prostate cancer (mCRPC).

Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).

Elisabeth I. Heath, MD, FACP, discusses a remaining challenge in nonmetastatic castration-resistant prostate cancer.

Elisabeth I. Heath, MD, FACP, discusses apalutamide, enzalutamide, and darolutamide, which have all been approved for use in nonmetastatic castration-resistant prostate cancer.

Elisabeth I. Heath, MD, FACP, discusses the safety profiles of apalutamide, enzalutamide, and darolutamide in nonmetastatic castration-resistant prostate cancer.